drugset / Trial / NCT00411307
A Randomized, Open-Label, Single-Dose, Small Study to Evaluate the Safety and Effectiveness of Hydromorphone in Patients With Short Term, Moderate to Severe Postoperative Pain
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this small study was to investigate the safety and effectiveness of OROS hydromorphone HCI for the treatment of short-term, moderate to severe postoperative pain following total knee replacement surgery.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- 2001-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydromorphone | Other / unclassified | 8 mg | — |
| Subject | Hydromorphone | Other / unclassified | 16 mg | — |
| Subject | Hydromorphone | Other / unclassified | 32 mg | — |
Indications
No indication recorded.